Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Discovery/Trans Medicine

Chief Financial Officer

Chief Executive Officer

COO and General Counsel

Chief Medical Officer

Chief Commercial Officer

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop JNJ-75220795, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-05-02	Premium	sold	Premium	Premium	Premium	-
2024-04-01	Premium	sold	Premium	Premium	Premium	Chief Discovery/Trans Medicine
2024-03-20	Premium	bought	Premium	Premium	Premium	-
2024-03-19	Premium	bought	Premium	Premium	Premium	-
2024-03-18	Premium	bought	Premium	Premium	Premium	-
2024-03-06	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2024-01-31	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer
2024-01-31	Premium	sold	Premium	Premium	Premium	Chief Executive Officer
2024-01-12	Premium	sold	Premium	Premium	Premium	Chief Discovery/Trans Medicine
2024-01-11	Premium	sold	Premium	Premium	Premium	-
2024-01-11	Premium	sold	Premium	Premium	Premium	-
2024-01-11	Premium	sold	Premium	Premium	Premium	-
2024-01-11	Premium	sold	Premium	Premium	Premium	-
2024-01-05	Premium	sold	Premium	Premium	Premium	COO and General Counsel
2024-01-05	Premium	sold	Premium	Premium	Premium	-
2024-01-05	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2024-01-05	Premium	sold	Premium	Premium	Premium	Chief Commercial Officer
2024-01-05	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2024-01-04	Premium	acquired	Premium	Premium	Premium	Chief Medical Officer
2024-01-04	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2024-01-04	Premium	acquired	Premium	Premium	Premium	COO and General Counsel
2024-01-04	Premium	acquired	Premium	Premium	Premium	-
2024-01-04	Premium	sold	Premium	Premium	Premium	COO and General Counsel
2024-01-04	Premium	acquired	Premium	Premium	Premium	Chief Commercial Officer
2024-01-03	Premium	sold	Premium	Premium	Premium	-

ARWR - Arrowhead Pharmaceuticals Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for ARWR